Insider Transactions in Q1 2021 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2021
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-0.82%
|
$3,362
$41.16 P/Share
|
|
Mar 22
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
978
+1.0%
|
$3,912
$4.31 P/Share
|
|
Mar 15
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.86%
|
$23,000
$46.77 P/Share
|
|
Mar 15
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$115,000
$46.77 P/Share
|
|
Mar 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Mar 10
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.72%
|
$312,500
$50.74 P/Share
|
|
Mar 10
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+0.71%
|
$12,500
$2.67 P/Share
|
|
Mar 05
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-7.96%
|
$240,000
$48.62 P/Share
|
|
Mar 05
2021
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.37%
|
$15,000
$3.2 P/Share
|
|
Mar 01
2021
|
Victoria L. Brown Program Team Lead |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+11.08%
|
-
|
|
Mar 01
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.03%
|
$28,800
$48.58 P/Share
|
|
Mar 01
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
2,000
-46.01%
|
$100,000
$50.0 P/Share
|
|
Mar 01
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+31.51%
|
$6,000
$3.76 P/Share
|
|
Mar 01
2021
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+14.35%
|
-
|
|
Feb 16
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$115,000
$46.0 P/Share
|
|
Feb 16
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Feb 16
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.85%
|
$23,000
$46.0 P/Share
|
|
Feb 10
2021
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-0.49%
|
$21,996
$47.72 P/Share
|
|
Feb 10
2021
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,523
-0.21%
|
$118,581
$47.72 P/Share
|
|
Feb 10
2021
|
Federico Grossi Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
688
-1.15%
|
$32,336
$47.72 P/Share
|
|
Feb 10
2021
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
144
-1.61%
|
$6,768
$47.72 P/Share
|
|
Feb 10
2021
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
688
-3.52%
|
$32,336
$47.72 P/Share
|
|
Feb 10
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
688
-0.08%
|
$32,336
$47.72 P/Share
|
|
Feb 10
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Payment of exercise price or tax liability
|
Direct |
153
-6.12%
|
$7,191
$47.72 P/Share
|
|
Feb 10
2021
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
858
-2.44%
|
$40,326
$47.72 P/Share
|
|
Feb 10
2021
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
680
-2.27%
|
$31,960
$47.72 P/Share
|
|
Feb 09
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
2,000
-44.44%
|
$100,000
$50.0 P/Share
|
|
Feb 09
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+30.77%
|
$6,000
$3.76 P/Share
|
|
Feb 01
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.0%
|
$26,400
$44.0 P/Share
|
|
Jan 28
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+0.54%
|
-
|
|
Jan 28
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jan 28
2021
|
Victoria L. Brown Program Team Lead |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+35.9%
|
-
|
|
Jan 28
2021
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+44.6%
|
-
|
|
Jan 28
2021
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+33.33%
|
-
|
|
Jan 28
2021
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+33.33%
|
-
|
|
Jan 28
2021
|
Lukas Scheibler Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+13.48%
|
-
|
|
Jan 28
2021
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+4.64%
|
-
|
|
Jan 28
2021
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+14.47%
|
-
|
|
Jan 28
2021
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+1.52%
|
-
|
|
Jan 28
2021
|
Federico Grossi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+7.21%
|
-
|
|
Jan 28
2021
|
Adam J. Townsend Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+19.27%
|
-
|
|
Jan 27
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
43,483
+22.35%
|
$173,932
$4.04 P/Share
|
|
Jan 27
2021
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
71,777
+2.98%
|
$287,108
$4.04 P/Share
|
|
Jan 25
2021
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+13.31%
|
$45,000
$3.48 P/Share
|
|
Jan 15
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$132,500
$53.15 P/Share
|
|
Jan 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Jan 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-10.04%
|
$204,000
$51.99 P/Share
|
|
Jan 04
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$114,000
$57.24 P/Share
|
|
Jan 04
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$6,000
$3.76 P/Share
|
|
Jan 04
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.48%
|
$34,200
$57.24 P/Share
|